DGDong Jin Go

Dong Jin Go

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dong Jin Go has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Yeong Wook Song

    Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Republic of Korea

    4 shared publications
  • Eun Young Lee

    Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

    2 shared publications
  • Jin Kyun Park

    Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine

    2 shared publications
  • Kichul Shin

    Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea

    2 shared publications
  • Yun Jong Lee

    Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

    2 shared publications
  • Ali Guermazi

    Department of Radiology Boston University School of Medicine Boston Massachusetts USA

    1 shared publication

Latest Publications

  • Open Access

    Psychotropic Drug Use in Korean Patients With Osteoarthritis

    by Seong-Hun Kang, Hyun Ah Kim, Insun Choi, Chan Mi Park, Hoyol Jhang, Jinhyun Kim, Dong Jin Go, Suhyun Jang

    Kang SH, et al. J Korean Med Sci. 2024 Dec;40:e53. https://doi.org/10.3346/jkms.2025.40.e53


  • Performance of cut-offs adjusted with positive control band intensity in line-blot assays for myositis-specific antibodies

    by Sung Hae Chang, Se Rim Choi, Yong Seok Choi, Dong Jin Go, Jun Won Park, You-Jung Ha, Jin Kyun Park, Eun Ha Kang, Eun Young Lee, Kichul Shin, et al.

    The diagnostic performance of band intensity (BI) cut-offs, adjusted by a positive control band (PCB) in a line-blot assay (LBA) for myositis-related autoantibodies (MRAs) is investigated. Sera from 153 idiopathic inflammatory myositis (IIM) patients with available immunoprecipitation assay (IPA) data and 79 healthy controls were tested using the EUROLINE panel. Strips were evaluated for BI using the EUROLineScan software, and the coefficient of variation (CV) was calculated. Sensitivity and specificity, area under the curve (AUC), and the Youden’s index (YI) were estimated at non-adjusted or PCB-adjusted cut-off values. Kappa statistics were calculated for IPA and LBA. Although inter-assay CV for PCB BI was 3.9%, CV was 12.9% in all samples, and a significant correlation was found between BIs of PCB and seven MRAs (all P < 0.05). At adjusted BI (aBI) > 10, the negative conversion rate of myositis-specific autoantibody (MSA)-positivity at BI > 10 was 11.5% in controls and 1.3% in patients. The specificity, AUC, and YI for MSAs at aBI > 10 or > 20 were higher than those at non-adjusted cut-off values. Additionally, AUC (0.720), YI (0.440), and the prevalence of MRAs with kappa > 0.60 (58.3%) were the highest at aBI > 20. The overall sensitivity and specificity for MSAs were 50.3% and 93.7% at aBI > 20, respectively, and 59.5% and 65.8% with BI > 10, respectively. The diagnostic performance of LBA can be improved using PCB-adjusted BIs. aBI > 20 is the optimal cut-off for IIM diagnosis using the EUROLINE LBA panel.


  • Metabolic obesity and the risk of knee osteoarthritis progression in elderly community residents: A 3‐year longitudinal cohort study

    by Dong Jin Go, Dong Hyun Kim, Ali Guermazi, Michel Daoud Crema, David J. Hunter, Hyun Sook Hwang, Hyun Ah Kim

    Objective: Metabolic syndrome is a major health problem worldwide associated with obesity, thus drawing attention to its relation to osteoarthritis (OA). However, it is still uncertain whether metabolic syndrome or body fat distribution is associated with knee OA. The aim of this longitudinal study was to elucidate the association between metabolic obesity and adverse structural changes of knee OA assessed by magnetic resonance imaging (MRI).Methods: Participants were recruited from the Hallym Aging Study cohort in Korea. Knee MRI scans, along with dual‐energy X‐ray absorptiometry, were assessed in 226 participants at baseline and after 3 years. The structural progression in the tibiofemoral joint was evaluated using the semi‐quantitative Whole‐Organ MRI Score (WORMS) for cartilage morphology and bone marrow lesions (BML). Logistic regression with generalized estimating equation was performed for associations of metabolic risk factors with worsening of WORMS scores at the subregional level.Results: In the medial compartment, fat mass in women was associated with cartilage loss, but the statistical significance disappeared after adjusting for body mass index. Metabolic syndrome and each of its components were not associated with cartilage loss or increase of BML. On the other hand, the interaction effects of metabolic syndrome on the association between obesity and knee OA progression were not significant.Conclusion: In this cohort, metabolic effects of obesity on knee cartilage damage and BML were not demonstrated. Further large‐scale studies are required to prove the causal relationship between metabolic obesity and knee OA.


  • Urinary vitamin D-binding protein, a novel biomarker for lupus nephritis, predicts the development of proteinuric flare

    by D J Go, J Y Lee, M J Kang, E Y Lee, E B Lee, E C Yi, Y W Song

    Lupus nephritis (LN) is a major complication of systemic lupus erythematosus (SLE). Conventional biomarkers for assessing renal disease activity are imperfect in predicting clinical outcomes associated with LN. The aim of this study is to identify urinary protein biomarkers that reliably reflect the disease activity or predict clinical outcomes. A quantitative proteomic analysis was performed to identify protein biomarker candidates that can differentiate between SLE patients with and without LN. Selected biomarker candidates were further verified by enzyme-linked immunosorbent assay using urine samples from a larger cohort of SLE patients (n = 121) to investigate their predictive values for LN activity measure. Furthermore, the association between urinary levels of a selected panel of potential biomarkers and prognosis of LN was assessed with a four-year follow-up study of renal outcomes. Urinary vitamin D-binding protein (VDBP), transthyretin (TTR), retinol binding protein 4 (RBP4), and prostaglandin D synthase (PTGDS) were significantly elevated in SLE patients with LN, especially in patients with active LN (n = 21). Among them, VDBP well correlated with severity of proteinuria (rho = 0.661, p < 0.001) and renal SLE Disease Activity Index (renal SLEDAI) (rho = 0.520, p < 0.001). In the four-year follow-up, VDBP was a significant risk factor (hazard ratio 9.627, 95% confidence interval 1.698 to 54.571, p = 0.011) for the development of proteinuric flare in SLE patients without proteinuria (n = 100) after adjustments for multiple confounders. Urinary VDBP correlated with proteinuria and renal SLEDAI, and predicted the development of proteinuria.


  • Pivotal factors for successful withdrawal of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis patients in remission or with low-disease activity

    by Dong Jin Go, Kichul Shin, Han Joo Baek, Seong Wook Kang, Young Mo Kang, Jae Bum Jun, Yun Jong Lee, Sung Hwan Park, Yeong Wook Song

    The purpose of this study is to examine the patient-reported outcomes (PRO) after discontinuing nonsteroidal anti-inflammatory drugs (NSAIDs) and clinical factors associated with a favorable outcome in patients with rheumatoid arthritis (RA) in remission or with low-disease activity (LDA). A 16-week prospective open-label trial was conducted at eight rheumatology clinics in Korea. RA patients with 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR) < 3.2 who were on NSAIDs for more than a month were enrolled, and NSAIDs were discontinued. Acetaminophen (AAP) was used as the rescue medication, and NSAIDs were restarted when joint pain was intolerable with AAP. The endpoint was to analyze the group of patients who continued to withdraw NSAIDs. Among 109 enrolled patients, 105 completed the 16-week follow-up. Eighty-nine (84.8%) patients remained without restarting NSAIDs. In these patients, there was a slight increase in their pain levels compared with baseline (median 14.0 versus 19.0 using the pain-visual analog scale, p = 0.010). However, changes in DAS28-ESR (p = 0.638) and routine assessment of patient index data 3 (RAPID-3) (p = 0.128) were insignificant. Moreover, 66 (62.9%) patients showed sustained effectiveness on PRO without restarting NSAIDs. In the multivariate regression models, joint swelling was the detrimental factor in NSAID withdrawal (odds ratio [OR] 0.149, 95% confidence interval [CI] 0.033–0.680, p = 0.014) and sustained effectiveness (OR 0.284, 95% CI 0.091–0.883, p = 0.030). Joint pain in RA patients in remission or with LDA can be well managed without NSAIDs, especially in those without swollen joints at the time of cessation.


  • Open Access

    Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study

    by Dong Jin Go, Eun Young Lee, Eun Bong Lee, Yeong Wook Song, Maximilian Ferdinand Konig, Jin Kyun Park

    Go DJ, et al. J Korean Med Sci. 2016 Mar;31(3):389-396. https://doi.org/10.3346/jkms.2016.31.3.389